Moomoo AI 已提取核心訊息
NexImmune, Inc. has announced the offering of 117,000 shares of its common stock at a purchase price of $12.05 per share to an institutional investor, as detailed in a securities purchase agreement dated February 2, 2024. Additionally, the company is offering pre-funded warrants to purchase up to 187,731 shares of common stock to the same purchaser, in lieu of common stock that would result in the purchaser owning more than 9.99% of NexImmune's outstanding common stock post-transaction. Each pre-funded warrant is exercisable for one share of common stock at a nominal exercise price of $0.001 per share and is immediately exercisable. The offering also includes a concurrent private placement of common stock warrants to purchase up to 304,731 shares of common stock, which are...Show More
NexImmune, Inc. has announced the offering of 117,000 shares of its common stock at a purchase price of $12.05 per share to an institutional investor, as detailed in a securities purchase agreement dated February 2, 2024. Additionally, the company is offering pre-funded warrants to purchase up to 187,731 shares of common stock to the same purchaser, in lieu of common stock that would result in the purchaser owning more than 9.99% of NexImmune's outstanding common stock post-transaction. Each pre-funded warrant is exercisable for one share of common stock at a nominal exercise price of $0.001 per share and is immediately exercisable. The offering also includes a concurrent private placement of common stock warrants to purchase up to 304,731 shares of common stock, which are not registered under the Securities Act and are being offered under an exemption. The common stock is listed on The Nasdaq Capital Market under the symbol 'NEXI.' The last reported sale price of NexImmune's common stock was $15.19 per share as of February 1, 2024. The securities offered are expected to be delivered on or about February 6, 2024, subject to customary closing conditions.
NexImmune, Inc.宣佈以每股12.05美元的收購價向機構投資者發行11.7萬股普通股，詳情見2024年2月2日的證券購買協議。此外，該公司還提供預先注資的認股權證，向同一買家購買多達187,731股普通股，以代替普通股，這將使買方在交易後擁有NexImmune已發行普通股的9.99％以上。每份預先注資的認股權證均可按每股0.001美元的名義行使價行使一股普通股，並可立即行使。此次發行還包括同時私募普通股認股權證，以購買多達304,731股普通股，這些普通股未根據《證券法》註冊，是根據豁免發行的。普通股在納斯達克資本市場上市，股票代碼爲 “NEXI”。截至2024年2月1日，NexImmune普通股上次公佈的銷售價格爲每股15.19美元。所發行的證券預計將於2024年2月6日左右交割，但須遵守慣例成交條件。
NexImmune, Inc.宣佈以每股12.05美元的收購價向機構投資者發行11.7萬股普通股，詳情見2024年2月2日的證券購買協議。此外，該公司還提供預先注資的認股權證，向同一買家購買多達187,731股普通股，以代替普通股，這將使買方在交易後擁有NexImmune已發行普通股的9.99％以上。每份預先注資的認股權證均可按每股0.001美元的名義行使價行使一股普通股，並可立即行使。此次發行還包括同時私募普通股認股權證，以購買多達304,731股普通股，這些普通股未根據《證券法》註冊，是根據豁免發行的。普通股在納斯達克資本市場上市，股票代碼爲 “NEXI”。截至2024年2月1日，NexImmune普通股上次公佈的銷售價格爲每股15.19美元。所發行的證券預計將於2024年2月6日左右交割，但須遵守慣例成交條件。
有用
沒用